TY - JOUR
T1 - Associated factors of fatigue in patients with COPD
T2 - results from the FAntasTIGUE study
AU - Van Herck, Maarten
AU - Goërtz, Yvonne M.J.
AU - Ebadi, Zjala
AU - Burtin, Chris
AU - Peters, Jeannette B.
AU - Thong, Melissa S.Y.
AU - Posthuma, Rein
AU - Muris, Jean W.M.
AU - Bischoff, Erik W.M.A.
AU - Wouters, Emiel F.M.
AU - Sprangers, Mirjam A.G.
AU - Vercoulen, Jan H.
AU - Janssen, Daisy J.A.
AU - Spruit, Martijn A.
N1 - Funding Information:
This project is supported by grant 4.1.16.085 of Lung Foundation Netherlands (Leusden, The Netherlands), AstraZeneca Netherlands, Boehringer Ingelheim Netherlands and Stichting Astma Bestrijding (Amsterdam, The Netherlands). Funding information for this article has been deposited with the Crossref Funder Registry.
Publisher Copyright:
© The authors 2025.
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Background Fatigue is present in about half of the patients with COPD. The associated factors of fatigue in COPD remain unclear and have not been studied in an integrated and holistic analysis. The aim of this study is to identify associated factors of fatigue in COPD. Methods In this cross-sectional study, clinically stable patients with COPD from primary and secondary care were assessed for fatigue (Checklist Individual Strength Subjective Fatigue (CIS-Fatigue)), other symptoms, medication, and personal, COPD-related, physical, psychological and systemic factors. Multivariable stepwise regression analyses were performed for each domain, followed by a multivariable (enter) model with all identified factors. Results In total, 247 patients with COPD (67±8 years, 60% male, forced expiratory volume in 1 s 57±21% predicted, 27% Global Initiative for Chronic Obstructive Lung Disease (GOLD) E) were included in the study of which 51% reported severe fatigue (CIS-Fatigue ?36 points). Distinct models for each group of factors identified the following factors associated with a higher level of fatigue: living alone, antidepressant use, anxiolytic use, systemic antihistamines use, higher Charlson comorbidity score, lower diffusion capacity, higher number of moderate exacerbations in the last year, higher dyspnoea, reduced sleep quality, higher pain, lower functional exercise capacity, higher fatigue-related catastrophising, more depressive symptoms, lower calcium and higher leukocyte count. The final model explained 46.6% of variance in fatigue with dyspnoea, sleep quality, fatigue-catastrophising and pain as significant associated factors (F(17, 184)=11.312, p<0.001). Conclusion Pain, sleep quality, dyspnoea and fatigue-catastrophising were identified as associated factors of fatigue. These factors should not be overlooked when treating fatigue in patients with COPD.
AB - Background Fatigue is present in about half of the patients with COPD. The associated factors of fatigue in COPD remain unclear and have not been studied in an integrated and holistic analysis. The aim of this study is to identify associated factors of fatigue in COPD. Methods In this cross-sectional study, clinically stable patients with COPD from primary and secondary care were assessed for fatigue (Checklist Individual Strength Subjective Fatigue (CIS-Fatigue)), other symptoms, medication, and personal, COPD-related, physical, psychological and systemic factors. Multivariable stepwise regression analyses were performed for each domain, followed by a multivariable (enter) model with all identified factors. Results In total, 247 patients with COPD (67±8 years, 60% male, forced expiratory volume in 1 s 57±21% predicted, 27% Global Initiative for Chronic Obstructive Lung Disease (GOLD) E) were included in the study of which 51% reported severe fatigue (CIS-Fatigue ?36 points). Distinct models for each group of factors identified the following factors associated with a higher level of fatigue: living alone, antidepressant use, anxiolytic use, systemic antihistamines use, higher Charlson comorbidity score, lower diffusion capacity, higher number of moderate exacerbations in the last year, higher dyspnoea, reduced sleep quality, higher pain, lower functional exercise capacity, higher fatigue-related catastrophising, more depressive symptoms, lower calcium and higher leukocyte count. The final model explained 46.6% of variance in fatigue with dyspnoea, sleep quality, fatigue-catastrophising and pain as significant associated factors (F(17, 184)=11.312, p<0.001). Conclusion Pain, sleep quality, dyspnoea and fatigue-catastrophising were identified as associated factors of fatigue. These factors should not be overlooked when treating fatigue in patients with COPD.
U2 - 10.1183/23120541.00857-2024
DO - 10.1183/23120541.00857-2024
M3 - Article
SN - 2312-0541
VL - 11
JO - ERJ Open Research
JF - ERJ Open Research
IS - 5
M1 - 00857-2024
ER -